Testosterone regulates smooth muscle contractile pathways in the rat prostate: Emphasis on PDE5 signaling

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 2, 2012, Pages

  Zhang, Xinhua ^a   Zang, Ning ^a   Wei, Yu ^a   Yin, Jin ^b   Teng, Ruobing ^a   Seftel, Allen ^c   Disanto, Michael E ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Children s Regional Hospital   (United States)

Author keywords

Benign prostatic hyperplasia; Contraction; Lower urinary tract symptoms; Nitric oxide; Phosphodiesterase 5; Phosphodiesterase 5 inhibitors; Smooth muscle myosin

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; CYCLIC GMP; MESSENGER RNA; MYOSIN; NEURONAL NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PHOSPHODIESTERASE V; PROTEIN ROKBETA; RHO KINASE; TESTOSTERONE; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IN VITRO STUDY; LOWER URINARY TRACT SYMPTOM; MALE; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; WESTERN BLOTTING;

ANDROGENS; ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III; ORCHIECTOMY; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATE; PURINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION; TESTOSTERONE;

EID: 84855305112     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00458.2011     Document Type: Article

References (78)

1. Adelstein RS, Eisenberg E. Regulation and kinetics of the actin-myosin-ATP interaction. Annu Rev Biochem 49: 921-956, 1980.
2. Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP. Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 51: 50-58, 2002.
3. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 30: 292-301, 2011.
4. Andric SA, Janjic MM, Stojkov NJ, Kostic TS. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway. Am J Physiol Endocrinol Metab 299: E544-E550, 2010.
5. Antonioli E, Cardoso AB, Carvalho HF. Effects of long-term castration on the smooth muscle cell phenotype of the rat ventral prostate. J Androl 28: 777-783, 2007.
6. Antonioli E, Della-Colleta HH, Carvalho HF. Smooth muscle cell behavior in the ventral prostate of castrated rats. J Androl 25: 50-56, 2004.
7. Auger-Pourmarin L, Roubert P, Chabrier PE. Alpha1-adrenoceptors in testosterone-induced prostatic hypertrophy. Eur J Pharmacol 341: 119-126, 1998.
8. Aydin M, Downing K, Villegas G, Zhang X, Chua R, Melman A, Disanto ME. The sphingosine-1-phosphate pathway is upregulated in response to partial urethral obstruction in male rats and activates RhoA/ Rho-kinase signalling. BJU Int 106: 562-571, 2010.
9. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5: 2170-2178, 2008.
10. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 8: 284-293, 2011.
11. Caine M. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology 32: 16-20, 1988.
12. Crone JK, Burnett AL, Chamness SL, Strandberg JD, Chang TS. Neuronal nitric oxide synthase in the canine prostate: aging, sex steroid, and pathology correlations. J Androl 19: 358-364, 1998.
13. DiSanto ME, Wang Z, Menon C, Zheng Y, Chacko T, Hypolite J, Broderick G, Wein AJ, Chacko S. Expression of myosin isoforms in smooth muscle cells in the corpus cavernosum penis. Am J Physiol Cell Physiol 275: C976-C987, 1998.
14. Eckert RE, Schreier U, Drescher P, Madsen PO, Derouet H, Becht E, Steffens J, Ziegler M. Regulation of prostatic smooth muscle contractility by intracellular second messengers: implications for the conservative treatment of benign prostatic hyperplasia. Urol Int 54: 6-21, 1995.
15. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D. Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci 54: 1595-1605, 1994.
16. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, Maggi M. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 7: 59-69, 2010.
17. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148: 1019-1029, 2007.
18. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 128: 836-839, 1982.
19. Gao F, Yang M, Luo CL, Wu XH. Local insulin-like growth factor-I of ventral prostate was upregulated during long-term castration and may function through the autocrine system. Prostate Cancer Prostatic Dis 14: 136-142, 2011.
20. Ghalayini IF. Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility. Int J Impot Res 16: 459-469, 2004.
21. Greco EA, Pili M, Bruzziches R, Corona G, Spera G, Aversa A. Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study. J Sex Med 3: 716-722, 2006.
22. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 50: 940-947, 2006.
23. Gu H, Martin H, Barsotti RJ, Labelle EF. Rapid increase in inositol phosphate levels in norepinephrine-stimulated vascular smooth muscle. Am J Physiol Cell Physiol 261: C17-C22, 1991.
24. Hib J, Magarinos GA. Effects of castration, androgen replacement and flutamide treatment on the contractile function of the rat prostate. Acta Physiol Pharmacol Latinoam 39: 281-287, 1989.
25. Homma Y, Hamada K, Nakayama Y, Tsujimoto G, Kawabe K. Effects of castration on contraction and alpha(1)-adrenoceptor expression in rat prostate. Br J Pharmacol 131: 1454-1460, 2000.
26. Huttunen E, Romppanen T, Helminen HJ. A histoquantitative study on the effects of castration on the rat ventral prostate lobe. J Anat 132: 357-370, 1981.
27. Kanika ND, Tar M, Tong Y, Kuppam DS, Melman A, Davies KP. The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol 297: C916-C927, 2009.
28. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51: 1717-1723, 2007.
29. Kashiwagi B, Shibata Y, Ono Y, Suzuki R, Honma S, Suzuki K. Changes in testosterone and dihydrotestosterone levels in male rat accessory sex organs, serum, and seminal fluid after castration: establishment of a new highly sensitive simultaneous androgen measurement method. J Androl 26: 586-591, 2005.
30. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 26: 603-609, 2008.
31. Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 55: 38-48, 2009.
32. Lacey JP, Donatucci CF, Price DT, Page SO, Bennett SA, Tenniswood MP, Schwinn DA. Effects of androgen deprivation on prostate alpha 1-adrenergic receptors. Urology 48: 335-341, 1996.
33. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 6: 544-552, 2009.
34. Lin AT, Chen MT, Chiang H, Yang CH, Chang LS. Effect of orchiectomy on the alpha adrenergic contractile response of dog prostate. J Urol 154: 1930-1933, 1995.
35. Lin VK, Wang D, Lee IL, Vasquez D, Fagelson JE, McConnell JD. Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue. Prostate 44: 193-203, 2000.
36. Liu CM, Lo YC, Wu BN, Wu WJ, Chou YH, Huang CH, An LM, Chen IJ. cGMP-enhancing-and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy. Prostate 67: 1397-1410, 2007.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] Method. Methods 25: 402-408, 2001.
38. Mancina R, Filippi S, Marini M, Morelli A, Vignozzi L, Salonia A, Montorsi F, Mondaini N, Vannelli GB, Donati S, Lotti F, Forti G, Maggi M. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod 11: 107-115, 2005.
39. Martínez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, Salonia A, Stief C. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol 60: 527-535, 2011.
40. McConnell JD. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate Suppl 3: 49-59, 1990.
41. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-2398, 2003.
42. McNicholas TA, Kirby RS, Lepor H. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Campbell-Walsh Urology, edited by Wein A, Kavoussi LR, Novick A, Partin AW, and Peters CA. Philadelphia, PA: Saunders, 2011, p. 2611-2654.
43. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97, Suppl 2: 23-28, 2006.
44. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071-1077, 2007.
45. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401-1407, 2007.
46. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145: 2253-2263, 2004.
47. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 8: 2746-2760, 2011.
48. Muller D, Mukhopadhyay AK, Davidoff MS, Middendorff R. Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: Tissuespecific changes with aging and in response to Leydig cell depletion. Reproduction 142: 333-343, 2011.
49. Nagasaki S, Nakano Y, Masuda M, Ono K, Miki Y, Shibahara Y, Sasano H. Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: An immunohistochemical study. BJU Int. In press.
50. + channel by nitric oxide in cultured human proximal tubule cells. Am J Physiol Renal Physiol 287: F411-F417, 2004.
51. Niu Y, Xu Y, Zhang J, Bai J, Yang H, Ma T. Proliferation and differentiation of prostatic stromal cells. BJU Int 87: 386-393, 2001.
52. O'Leary MP, Roehrborn CG, Black L. Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer Prostatic Dis 11: 129-133, 2008.
53. Passmore JC, Joshua IG, Rowell PP, Tyagi SC, Falcone JC. Reduced alpha adrenergic mediated contraction of renal preglomerular blood vessels as a function of gender and aging. J Cell Biochem 96: 672-681, 2005.
54. Roehrborn CG. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology and natural history. In: Campbell-Walsh Urology, edited by Wein A, Kavoussi LR, Novick A, Partin AW, and Peters CA. Philadelphia, PA: Saunders, 2011, p. 2570-2610.
55. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 7, Suppl 9: S3-S14, 2005.
56. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180: 1228-1234, 2008.
57. Saito M, Ohmasa F, Shomori K, Dimitriadis F, Ohiwa H, Shimizu S, Tsounapi P, Kinoshita Y, Satoh K. Rhos and Rho kinases in the rat prostate: their possible functional roles and distributions. Mol Cell Biochem 358: 207-213, 2011.
58. Sarma AP, Pidaparti RM, Meiss RA. Effect of off-axis cell orientation on mechanical properties in smooth muscle tissue. J Biomed Sci Eng 4: 10-17, 2011.
59. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236-1244, 2008.
60. Suematsu N, Satoh S, Kinugawa S, Tsutsui H, Hayashidani S, Nakamura R, Egashira K, Makino N, Takeshita A. α1-Adrenoceptor-Gq-RhoA signaling is upregulated to increase myofibrillar Ca2 sensitivity in failing hearts. Am J Physiol Heart Circ Physiol 281: H637-H646, 2001.
61. Sward K, Mita M, Wilson DP, Deng JT, Susnjar M, Walsh MP. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 5: 66-72, 2003.
62. + sensitization in the contraction of human prostate. Neurourol Urodyn 26: 547-551, 2007.
63. Thiyagarajan M, Kaul CL, Ramarao P. Enhancement of alpha-adrenoceptor-mediated responses in prostate of testosterone-treated rat. Eur J Pharmacol 453: 335-344, 2002.
64. Tokanovic S, Malone DT, Ventura S. Stimulation of epithelial CB1 receptors inhibits contractions of the rat prostate gland. Br J Pharmacol 150: 227-234, 2007.
65. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2: 759-770, 2005.
66. Tschakovsky ME, Sujirattanawimol K, Ruble SB, Valic Z, Joyner MJ. Is sympathetic neural vasoconstriction blunted in the vascular bed of exercising human muscle? J Physiol 541: 623-635, 2002.
67. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484-2490, 2001.
68. Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol 72: 197-204, 2011.
69. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP-and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49: 740-745, 2006.
70. Vignozzi L, Morelli A, Filippi S, Ambrosini S, Mancina R, Luconi M, Mungai S, Vannelli GB, Zhang XH, Forti G, Maggi M. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 4: 620-630, 2007.
71. Waldkirch ES, Uckert S, Langnase K, Richter K, Jonas U, Wolf G, Andersson KE, Stief CG, Hedlund P. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 52: 495-501, 2007.
72. Wang JM, McKenna KE, Lee C. Determination of prostatic secretion in rats: effect of neurotransmitters and testosterone. Prostate 18: 289-301, 1991.
73. Wingard CJ, Johnson JA, Holmes A, Prikosh A. Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol 284: R1572-R1579, 2003.
74. Zenzmaier C, Sampson N, Pernkopf D, Plas E, Untergasser G, Berger P. Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. Endocrinology 151: 3975-3984, 2010.
75. Zhang X, Kanika ND, Melman A, Disanto ME. Smooth Muscle Myosin Expression, Isoform Composition and Functional Activities in Rat Corpus Cavernosum Altered by the Streptozotocin-Induced Type 1 Diabetes. Am J Physiol Endocrinol Metab. First published September 13, 2011; doi: 10.1152/ajpendo.00231.2011.
76. Zhang XH, Filippi S, Morelli A, Vignozzi L, Luconi M, Donati S, Forti G, Maggi M. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 3: 253-264, 2006.
77. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 47: 409-416, 2005.
78. Zhao GQ, Holterhus PM, Dammshauser I, Hoffbauer G, Aumuller G. Estrogen-induced morphological and immunohistochemical changes in stroma and epithelium of rat ventral prostate. Prostate 21: 183-199, 1992